Microbicide News and Research

RSS

A Microbicide is any substance or process that kills germs (bacteria, viruses, and other microorganisms that can cause infection and disease). Also called germicide.

AIDS 2010 follow-up coverage: Global HIV/AIDS funding; HIV/AIDS studies, releases

Media outlets continued to reflect on news from the International AIDS Conference-AIDS 2010, which attracted over 19,000 participants from 197 countries to Vienna last week, according to the conference blog.

30 Jul 2010

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

Chimerix, Inc., a biopharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of research results demonstrating the potential of CMX157 (hexadecyloxypropyl tenofovir) to effectively suppress replication of human immunodeficiency virus (HIV) that cannot be treated with currently available nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), including tenofovir disoproxil fumarate (Viread), due to the development of multi-drug resistance. Earlier this year, Chimerix initiated a dose-escalating Phase 1 clinical trial of CMX-157 to evaluate drug safety, tolerability and pharmacokinetics.

29 Jul 2010

New York Times examines questions left unanswered by microbicide trial

The New York Times examines a set of questions raised by news out of the International AIDS Conference-AIDS 2010 last week that a microbicide gel containing the antiretroviral tenofovir used by women before and after sex helped reduce their risk of HIV infection by 39 percent.

28 Jul 2010

Global Fund director calls on emerging countries to invest more in programs to reduce HIV/AIDS, TB and malaria at AIDS 2010

On the final day of the International AIDS Conference-AIDS 2010 Friday, Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria called upon "China, India and other fast-growing economies" to chip in to help close the funding gap in efforts to battle HIV/AIDS, Agence France-Presse reports. "Until now, these countries have been recipients of AIDS funds, not donors," the news service writes.

27 Jul 2010

Einstein scientists awarded $4.1M to test microbicide Carraguard against HPV

The National Cancer Institute has awarded Albert Einstein College of Medicine of Yeshiva University $4.1 million to test the microbicide Carraguard- against the human papillomavirus, which causes cervical cancer. The research will evaluate the efficacy of Carraguard- - a clear gel made from the seaweed derivative carrageenan - in preventing new HPV infections in women.

26 Jul 2010

AVAC releases GPP Guidelines at International AIDS Conference

The draft second edition of The Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials were released yesterday at the International AIDS Conference in Vienna by AVAC. The GPP Guidelines aim to provide trial funders, sponsors, and implementers with systematic guidance on how to effectively work with a range of stakeholders as they design and conduct biomedical HIV prevention trials.

23 Jul 2010

New era of scientific innovation to drive novel ways of treating, preventing HIV

The unwillingness of the global AIDS community to accept the status quo is fuelling a new era of scientific innovation to drive novel ways of treating and preventing HIV, organizers of the XVIII International AIDS Conference taking place in Vienna, Austria said today. And, with millions of lives dependent on expanding access to antiretroviral treatment to all those clinically in need, researchers and clinicians are partnering in new ways to find the most effective and efficient methods to deliver treatment and strengthen health systems.

22 Jul 2010

Smoking cessation effectively alter subgingival microbiome in patients on periodontal therapy: Study

Patients with chronic gum disease who quit smoking in addition to undergoing nonsurgical therapy not only demonstrated a lower abundance of harmful oral pathogens, but also an increase in health-associated bacteria. The researchers from The Ohio State University, Columbus Ohio, and Newcastle University, United Kingdom report their findings in the July 2010 issue of the Journal of Clinical Microbiology.

22 Jul 2010

Study marks significant milestone for microbicide research field, HIV prevention

Today we congratulate the Centre for the AIDS Programme of Research in South Africa and the people of South Africa on the positive findings from the CAPRISA 004 microbicide study, which marks a significant milestone both for the microbicide research field and HIV prevention as a whole.

22 Jul 2010

Flat global funding for HIV prevention research could have serious consequences: Report

Following significant advances in vaccine and microbicide research, including results presented today of 39% efficacy in the CAPRISA 004 microbicide gel trial among women in South Africa, a new report released today warns that flat funding for HIV prevention research may limit researchers' ability to quickly move promising approaches forward.

22 Jul 2010

AIDS 2010 opinions: U.S. AIDS funding; Human rights and HIV; Invest in primary care; Microbicide gel's possibilities

"Having met President [Barack] Obama, I'm confident that he's a man of conscience who shares my commitment to bringing hope and care to the world's poor. But I am saddened by his decision to spend less than he promised to treat AIDS patients in Africa," Desmond Tutu, archbishop emeritus of Cape Town and honorary chairman of the Global AIDS Alliance, writes in a New York Times opinion piece.

22 Jul 2010

Quick-Med Technologies receives USPTO Notice of Allowance for key NIMBUS antimicrobial technology patent

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a key patent related to the Company's proprietary NIMBUS® antimicrobial technology.

21 Jul 2010

HIV and Human Rights March to prevent new infections, provide treatment for people with HIV

The call for human rights as a fundamental component of efforts to prevent new infections and provide treatment for people living with HIV pervaded the XVIII International AIDS Conference today as delegates and local residents prepared for the HIV and Human Rights March through the streets of Vienna this evening. Conference participants are giving voice to the conference theme of Rights Here, Right Now through a number of plenary presentations, sessions, and Global Village and Youth Programme activities.

21 Jul 2010

AIDS 2010: Study finds microbicide containing HIV drug lowers infection risk in women by 39%

A microbicide gel containing Gilead's HIV drug tenofovir used by women before and after sex has been shown to reduce their risk of HIV infection by nearly 40%, according to a study unveiled at the International AIDS Conference-AIDS 2010, Reuters reports

21 Jul 2010

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) drug called tenofovir found its use before and after sex was significantly more protective against HIV infection than a placebo gel among women at high risk of HIV. Results of the study, known as CAPRISA 004, are to be reported at the International AIDS Conference (AIDS 2010) in Vienna and published online by the journal Science.

20 Jul 2010

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria. The CAPRISA 004 trial, which tested the safety and effectiveness of 1% tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided moderate protection against sexually transmitted HIV.

20 Jul 2010

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

"This is a historic day for HIV prevention research. The CAPRISA 004 results are the first clinical evidence that a microbicide gel can help to prevent sexual transmission of HIV infection," said AVAC Executive Director Mitchell Warren, reacting to the results of the landmark microbicide trial presented today at the International AIDS Conference in Vienna.

20 Jul 2010

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Researchers have achieved an important scientific breakthrough in the fight against HIV and genital herpes with a vaginal gel that significantly reduces a woman's risk of being infected with these viruses. The results of the ground-breaking safety and effectiveness study of an antiretroviral microbicide gel study were reported today by the Centre for the AIDS Programme of Research in South Africa at the XVIII International AIDS Conference in Vienna, Austria.

20 Jul 2010

USAID Administrator issues statement on CAPRISA 004 trial for preventing HIV infection in women

USAID is proud to be the major funder of the first-ever proof of concept that a microbicide can effectively and safely reduce the transmission of HIV from men to vulnerable women. An achievement of this magnitude could not have been possible without collaboration among governments, scientists, communities, and individual women at risk of HIV.

20 Jul 2010

New microbicide gel reduces woman's risk of being infected with HIV, genital herpes

Today at the XVIII International AIDS Conference in Vienna, Austria, members of the International Rectal Microbicide Advocates (IRMA) and thousands of other HIV advocates and scientists cheered a long-awaited, much anticipated success in the quest for new HIV prevention technologies. Researchers announced that a vaginal gel has been shown to significantly reduce a woman's risk of being infected with HIV and genital herpes

20 Jul 2010

Microbicide News and Research

AIDS 2010 follow-up coverage: Global HIV/AIDS funding; HIV/AIDS studies, releases

CMX157 shows potential to suppress replication of HIV in Phase 1 clinical trial

New York Times examines questions left unanswered by microbicide trial

Global Fund director calls on emerging countries to invest more in programs to reduce HIV/AIDS, TB and malaria at AIDS 2010

Einstein scientists awarded $4.1M to test microbicide Carraguard against HPV

AVAC releases GPP Guidelines at International AIDS Conference

New era of scientific innovation to drive novel ways of treating, preventing HIV

Smoking cessation effectively alter subgingival microbiome in patients on periodontal therapy: Study

Study marks significant milestone for microbicide research field, HIV prevention

Flat global funding for HIV prevention research could have serious consequences: Report

AIDS 2010 opinions: U.S. AIDS funding; Human rights and HIV; Invest in primary care; Microbicide gel's possibilities

Quick-Med Technologies receives USPTO Notice of Allowance for key NIMBUS antimicrobial technology patent

HIV and Human Rights March to prevent new infections, provide treatment for people with HIV

AIDS 2010: Study finds microbicide containing HIV drug lowers infection risk in women by 39%

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

USAID Administrator issues statement on CAPRISA 004 trial for preventing HIV infection in women

New microbicide gel reduces woman's risk of being infected with HIV, genital herpes

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News